Modulation of RAAS-natriuretic peptides in the treatment of HF: Old guys and newcomers

详细信息    查看全文

• 作者：Vincenzo Mollace^a ; Micaela Gliozzi^a ; ^{micaela.gliozzi@gmail.com} ; Annalisa Capuano^b ; Francesco Rossi^b
• 关键词：Renin&ndash ; angiotensin&ndash ; aldosterone system ; Heart failure ; RAAS inhibitors ; AT1-receptor modulators ; AT2-receptor modulators
• 刊名：International Journal of Cardiology
• 出版年：2017
• 出版时间：1 January 2017
• 年：2017
• 卷：226
• 期：Complete
• 页码：126-131
• 全文大小：506 K
• 卷排序：226

文摘

The use of renin–angiotensin–aldosterone system (RAAS) inhibitors in the treatment of chronic heart failure (HF) and arterial hypertension is recommended by the European Society of Cardiology Guidelines on the basis of consolidated evidence supporting their efficacy in the development of such a disease. However, the high incidence of re-hospitalization and mortality in patients undergoing chronic HF, leads to the need for the development of novel RAAS inhibitors possessing a better pharmacokinetic/pharmacodynamics profile in approaching hemodynamic imbalance and myocardial dysfunction associated with the development of chronic HF.Here we summarize some of the recent advances in the area of RAAS-modulators, including novel renin inhibitors, mineralcorticoid receptor antagonists and novel AT1 and AT2-receptor modulators. In addition, the pharmacology of a new class of compounds which display both AT1-receptor blocking properties combined with inhibition of neprilysin, the vasopeptidase enzyme degradating natriuretic peptide (ARNi), will be reviewed, alongside with their impact in the pathophysiology of chronic HF.